Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise.
The company’s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.
The Boston Globe9d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
That makes it less addictive than opioids, which were involved in about 70,000 overdose deaths for the year ending June 2024.
BioPharma Dive10d
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...
ENDPOINTS NEWS9d
Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study
Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition ...
BioPharma Dive9d
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
Interesting Engineering14h
From cuddles to cure: How ‘love hormone’ could tackle chronic gut pain
“Chronic abdominal pain is complex because it involves multiple mechanisms, including inflammation, altered gut motility, and heightened sensitivity of the nervous system,” Muttenhalter told IE. “The ...
Yahoo9d
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug
Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain. "People Don't Understand How Dangerous It Can Be ...
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- , (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the ...
Investing8d
Channel Therapeutics advances non-opioid pain treatment
However, the company's forward-looking statements regarding the potential success of their drugs and market opportunities ... pre-clinical trials of its non-opioid pain treatments.